Characterization of patients and evaluation of drug treatment for Multiple Sclerosis

Recruiting

• Conditions: Multiple Sclerosis Relapsing-Remitting; C10.114.375.500

• Registration Number: RBR-9x6yxbv
• Lead Sponsor: niversidade Federal de Mato Grosso do Sul

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-12-29
• Last Update Posted: 29 May 2023
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Individuals over 18 years of age; of both sexes; diagnosed with Multiple Sclerosis represented by the G-35 code, which encompasses the group of diseases of the nervous system in the 10th edition of the International Statistical Classification of Diseases and Related Health Problems (ICD 10); assisted by the Specialized component of the Pharmaceutical Assistance of Mato Grosso do Sul; undergoing treatment, for at least three months, with one of the following oral administration medications: Teriflunomide 14mg, Dimethyl fumarate 240mg or Fingolimod 0.5mg; with at least one result of the Expanded Disability Status Scale (EDSS) prior to and one subsequent to the initiation of treatment with the oral medications described above

Exclusion Criteria

Individuals with cognitive alterations that make it difficult to remember facts related to their illness; individuals with cognitive alterations that make it difficult to understand the research

Study & Design

• Study Type: Observational
• Study Design: Not specified